"目录号: HY-14602
Tramiprosate是一个小的，能够口服的化合物，可以结合可溶性Aβ，减少淀粉样蛋白聚合和随后的沉积。
相关产品
Deferoxamine mesylate-FPS-ZM1-Semagacestat-Geniposide-Frentizole-ARN2966-K 01-162-Notoginsenoside R1-amyloid P-IN-1-Carbazochrome sodium sulfonate-gamma-Secretase Modulators-Hoechst 34580-Schisantherin B-Amyloid beta-peptide(25-35)-
生物活性
Description
Tramiprosate is a small, orally-administered compound that binds to soluble Aβ and reduces amyloid aggregation and subsequent depositiontarget: AβIn vitro: Tramiprosate provides neuroprotection against Aβ-induced neurotoxicity in neuronal and mouse organotypic hippocampal cultures, and reverses Aβ-induced long-term potentiation (LTP) inhibition in rat hippocampus, in part, through activation of β-aminobutyric acid A (GABA-A) receptors. Tramiprosate dose-dependently provides neuroprotection against ischemic stroke.In vivo: Tramiprosate produced dose-dependent reductions of Aβ in the brain of transgenic mice (hAPP-TgCRND8). Clinical studies show that tramiprosate was safe and tolerable. In mild-to-moderate AD patients tramiprosate also reduced Aβ42 levels in CSF.The reference for animal administration is 50 mg/kg.
Clinical Trial
Bellus Health Inc
Alzheimer's Disease
May 2006
Phase 3
View MoreCollapse
References
